IMMX(IMMX)
IMMX
ANALYST COVERAGE4 analysts
BUY
▲ +93.1%upside to target
L $14.00
Med $17.00consensus
H $20.00Key MetricsTTM
Market Cap$479.09M
Revenue TTM$0.00
Net Income TTM-$34.98M
Free Cash Flow-$32.77M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-73.2%
Return on Assets-36.5%
Debt / Equity0.01
Current Ratio8.76
EPS TTM$-0.91
PRICE
Prev Close
8.67
Open
8.53
Day Range8.47 – 8.99
8.47
8.99
52W Range1.87 – 11.61
1.87
11.61
71% of range
VOLUME & SIZE
Avg Volume
841.5K
FUNDAMENTALS
P/E Ratio
-9.6x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
44
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 119 days
Sep 18
IMMX News
About
No description available.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Graham Ross FFPMChief Medical Officer & Head of Clinical Development
Ilya RachmanCo-Founder, CEO, Chief Scientific Officer & Chairman
Gabriel MorrisPresident, CFO & Director
Sean SennCo-Founder
David MarksChief Medical Officer of Cell Therapy
Vladimir TorchilinScientific Co-Founder
Mel Davis-PickettHead of CMC Technical Development
Michael A. GrabowChief Commercial Officer